CT测内脏肥胖与肌肉量对晚期卵巢癌手术结局的影响
该回顾性队列纳入2006–2017年FIGO 3/4期卵巢癌患者298例,用术前CT在L3-L4层面测内脏脂肪面积、总骨骼肌量和总脂肪面积,内脏肥胖定义为内脏脂肪≥100cm²。结果显示内脏肥胖者并发症更多(43% vs 21%,P<0.001),血栓事件更多(4.9% vs 0.6%,p=0.019);内脏肥胖、高血压和手术时长是术后并发症预测因素,肌肉量不是。
要点
- 内脏肥胖(≥100cm²)与晚期卵巢癌减瘤术后并发症风险升高相关。
- 内脏肥胖患者血栓事件发生率更高(4.9% vs 0.6%)。
- 肌肉量不是术后并发症的预测因素。
核心结论
- 内脏肥胖与晚期卵巢癌减瘤术后并发症发生率更高相关。
研究设计与样本
- 回顾性队列研究,纳入2006–2017年FIGO 3或4期卵巢癌患者298例,来自九家转诊医院。
- 术前CT在L3-L4单层测量内脏脂肪面积、总骨骼肌量和总脂肪面积,内脏肥胖定义为内脏脂肪≥100cm²。
主要发现
- 内脏肥胖患者高血压比例更高(38% vs 17%,p<0.001),ASA 3评分比例更高(21% vs 10%,P=0.012)。
- 内脏肥胖患者并发症发生率更高(43% vs 21%,P<0.001)。
- 血栓事件在内脏肥胖患者中占4.9%,非内脏肥胖患者中占0.6%(p=0.019)。
- 多因素分析显示内脏肥胖(OR: 4.37,p<0.001)、高血压(OR:1.9,p=0.046)和手术时长(OR: 1.004,p=0.017)是术后并发症预测因素。
- 肌肉量不是并发症的预测因素。
临床怎么用
- 对晚期卵巢癌减瘤手术患者,可参考术前CT评估的内脏肥胖(内脏脂肪≥100cm²)识别术后并发症高风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Visceral obesity (VO) is a risk factor for developing postoperative complications in patients undergoing abdominal oncological surgery. However, in ovarian cancer patients this influence of body composition on postoperative morbidity is not well established. The aim of this study is to assess the association between body composition and complications in patients with advanced ovarian cancer undergoing cytoreductive surgery. METHODS: Patients with FIGO stage 3 or 4 ovarian cancer between 2006 and 2017 were included. Visceral fat area, total skeletal mass and total fat area were measured on a single slice on the level of L3-L4 of the preoperative CT-scan. VO was defined as visceral fat ≥100cm2. The perioperative data were extracted retrospectively. A multivariate logistic regression analysis was performed to test the predictive value of multiple variables such as body composition, albumin levels and preoperative morbidity. RESULTS: 298 consecutive patients out of nine referring hospitals were included. VO patients were more likely to be hypertensive (38% vs 17% p < 0.001), and to have an ASA 3 score (21% vs 10% P = 0.012). Complications occurred more often in VO patients (43% vs 21% P < 0.001). Thrombotic events were found in 4.9% of VO patients versus 0.6% of the non-visceral obese patients (p = 0.019). VO(OR: 4.37, p < 0.001), hypertension (OR:1.9, p = 0.046) and duration of surgery (OR: 1.004, p = 0.017) were predictors of post-surgical complications. Muscle mass is not a predictor of complications. CONCLUSION: Visceral obesity is associated with a higher occurrence of complications in patients with advanced ovarian cancer undergoing cytoreductive surgery.
引用
- Heus C, Smorenburg A, Stoker J, et al. Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study. Gynecol Oncol. 2020. PMID: 33393479. doi:10.1016/j.ygyno.2020.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。